Expert Interview
Third View: Discussing Akero Therapeutics' Phase 2b results for efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH).
Ticker(s): AKROInstitution: Northwestern
- Assistant Professor of Medicine and Preventive Medicine in the Division of GI & Hepatology at Northwestern Feinberg School of Medicine.
- Co-director of the Northwestern Fatty Liver Program and helped to initiate the heart-liver transplant program at Northwestern in 2018.
- Clinical practice focuses on the management of patients with a nonalcoholic fatty liver disease and patients with disorders of both the heart and liver; PI of the Advancing Liver Therapeutic Approaches (ALTA) consortium.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
